多西紫杉醇联合吉西他滨治疗晚期非小细胞肺癌的临床观察  

The Clinical Observation of Docetaxel Combined with Gemcitabine in the Treatment of Advanced Patients with Non-small-cell Lung Cancer

作　　者：陈英[1] 

机构地区：[1]江苏省启东市第三人民医院内科,226200

出　　处：《医学理论与实践》2008年第12期1384-1386,共3页The Journal of Medical Theory and Practice

摘　　要：目的：观察非铂类药物多西紫杉醇（艾素）和吉西他滨（泽菲）联合治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法：37例NSCLC给予泽菲1 000mg/m2,第1天和第8天静脉滴注30min,艾素75mg/m2,第8天静脉滴注1h,21d为一个周期,至少治疗2个周期。结果：全组33例可评价疗效,CR 1例,PR 11例,总有效率为39.4%（CR＋PR）,SD45.5%（15/33）,PD18.2%（6/33）,中位生存期为11个月,疾病进展时间为6.5个月;1年生存率为48.5%（16/33）。不良反应主要是骨髓抑制,其中Ⅲ-Ⅳ度白细胞下降有31.4%,Ⅲ-Ⅳ度血小板下降有23.5%;非血液学毒性表现为恶心及呕吐,Ⅰ-Ⅱ度有23.1%,无Ⅲ-Ⅳ度恶心及呕吐。结论：多西紫杉醇联合吉西他滨对于晚期NSCLC疗效较理想,不良反应较低,对于提高生活质量有意义,是可以替代铂类药物的有效方案。Objective：To estimate the efficacy, toxicity and side effects of the combinations of gemcitabine and docetaxel in the treatment of advanced patients with non-small cell lung cancer （NSCLC）. Methods： 37 advanced patients with NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received gemcitabine 1 000 mg/m^2 on the 1st,8th day and docetaxel 75mg/m^2 in the 8th day. Both regiments had 21-day cycle, three weeks repeated and the efficacy was estimated after 2 periods. Results： The overall response rate was 39. 4% （12/33）, SD 45. 5% （ 15/33）, and PD18. 2%（6/33）. The median overall survival of the whole group was 11 months,TTP was 6. 5 months, the survival rate for 1-year survival time was 48. 5%. The Ⅲ-Ⅳ leucopenia was31.4%, but the Ⅲ-Ⅳ thromasthenia was 23. 5%, nausea and vomiting were mild to moderate. Conclusion： Gemcitabine plus docetaxel is an active and well-tolerated regimen and represents an option for treatment of the patients with advanced NSCLC.

关 键 词：吉西他滨 多西紫杉醇 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]